RWJ 445167

Drug Profile

RWJ 445167

Alternative Names: 3DP 10017; RWJ-445167

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Developer Johnson & Johnson; Zosano Pharma
  • Class Antithrombotics; Guanidines
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 02 Sep 2016 Discontinued - Clinical-Phase-Unknown for Thrombosis (PO)
  • 29 Sep 2015 Preclinical trials in Thrombosis in USA (Transdermal)
  • 01 Jul 2006 Clinical trials in Thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top